Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

54.27
+3.717.34%
Post-market: 55.421.15+2.12%19:57 EDT
Volume:5.56M
Turnover:305.32M
Market Cap:8.31B
PE:19.60
High:56.87
Open:51.10
Low:49.97
Close:50.56
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:3.94
T/O Rate:3.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:13.75
PE(LYR):19.59

Loading ...

BUZZ-TG Therapeutics rises as early-stage data shows benefit in rare muscle weakness disease

Reuters
·
Jun 09

TG Therapeutics launches Phase 2 trial testing Briumvi maintenance after efgartigimod in myasthenia gravis

Reuters
·
Jun 09

TG Therapeutics - Subcutaneous Briumvi Generally Well Tolerated With Safety Profile Consistent With Iv Formulation

THOMSON REUTERS
·
Jun 09

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous Briumvi in Patients With Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

THOMSON REUTERS
·
Jun 09

TG Therapeutics - Initiates Phase 2 Trial of Briumvi as Maintenance Therapy After Efgartigimod Induction in Mg

THOMSON REUTERS
·
Jun 09

Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), TG Therapeutics (TGTX) and Dexcom (DXCM)

TIPRANKS
·
Jun 04

B. Riley Securities Remains a Buy on TG Therapeutics (TGTX)

TIPRANKS
·
Jun 04

TG Therapeutics rises 10.6%

TIPRANKS
·
Jun 04

BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway

Reuters
·
Jun 03

Analysts’ Top Healthcare Picks: TG Therapeutics (TGTX), AbbVie (ABBV)

TIPRANKS
·
Jun 03

BUZZ-U.S. STOCKS ON THE MOVE-Ollie's Bargain Outlet Holdings, Steel Dynamics

Reuters
·
Jun 03

TG Therapeutics Reports Positive Phase 1 Data for Subcutaneous Multiple Sclerosis Therapy

MT Newswires Live
·
Jun 03

TG Therapeutics announces results from Briumvi trial

TIPRANKS
·
Jun 03

BUZZ-TG Therapeutics rises on positive early data for subcutaneous multiple sclerosis drug

Reuters
·
Jun 03

TG Therapeutics reports positive data for subcutaneous BRIUMVI

TIPRANKS
·
Jun 03

TG Therapeutics - Subcutaneous Briumvi Well-Tolerated With No New Safety Signals Observed

THOMSON REUTERS
·
Jun 03

TG Therapeutics Announces Positive Results From Phase 1 Trial Evaluating Subcutaneous Briumvi® (Ublituximab-Xiiy)

THOMSON REUTERS
·
Jun 03

TG Therapeutics - Topline Phase 3 Data for Subcutaneous Briumvi Expected Year-End 2026 or Early 2027

THOMSON REUTERS
·
Jun 03

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

GlobeNewswire
·
Jun 03

TG Therapeutics Announces Publication of Post-Hoc Data From the Phase 3 Ultimate I & Ii Trials in Treatment Naive Patients With Relapsing Forms of MS Published in Frontiers in Immunology

THOMSON REUTERS
·
Jun 01